History of C2 monitoring in heart and liver transplant patients treated with cyclosporine microemulsion

Transplantation Proceedings

Volumn 36, Issue 2 SUPPL., 2004, Pages S442-S447

  Cantarovich, M ^a   Barkun, J ^a   Giannetti, N ^a   Cecere, R ^a   Besner, J G ^b   Tchervenkov, J ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; COMPLEMENT COMPONENT C2; CYCLOSPORIN A; THYMOCYTE ANTIBODY; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ANESTHESIA INDUCTION; AREA UNDER THE CURVE; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MONITORING; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; LIVER TRANSPLANTATION; MAINTENANCE THERAPY; MICROEMULSION; PRIORITY JOURNAL; REVIEW; BLOOD; DRUG ANTAGONISM; EMULSION; HISTORY; IMMUNOLOGY; ORAL DRUG ADMINISTRATION; PHYSIOLOGY;

ADMINISTRATION, ORAL; CALCINEURIN; CYCLOSPORINE; DRUG MONITORING; EMULSIONS; HEART TRANSPLANTATION; HISTORY, 20TH CENTURY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION;

EID: 1642341277     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.01.004     Document Type: Article

References (42)

1. Morris P.J. Cyclosporine A. Transplantation. 32:1981;349.
2. Miller L.W., O'Connell J.B. Long-term use of cyclosporine in cardiac transplantation. Transplant Proc. 22:1990;15.
3. Myers B.D., Ross J., Newton L., et al. Cyclosporine associated chronic nephropathy. N Engl J Med. 311:1984;699.
4. Mihatsch M.J., Thiel G., Spichtin H.P., et al. Morphological findings in kidney transplant after treatment with cyclosporine. Transplant Proc. 4:1983;2821.
5. Platz K.P., Mueller A.R., Blumhardt G., et al. Nephrotoxicity following orthotopic liver transplantation. Transplantation. 58:1994;170.
6. Winkler M., Brinkmann C., Jost U., et al. Long-term side effects of cyclosporine-based immunosuppression in patients after liver transplantation. Transplant Proc. 26:1994;2679.
7. Greenberg A., Egel J.W., Thompson M.E., et al. Early and late form of cyclosporine nephrotoxicity studies in cardiac transplant patients. Am J Kidney Dis. 9:1987;12.
8. Lewis R.M., Van Buren C.T., Radovancevic B., et al. Impact of long-term cyclosporine immunosuppressive therapy on native kidneys versus renal allografts serial renal function in heart and kidney transplant recipients. J Heart Lung Transplant. 10:1991;63.
9. Gonwa T.A., Mai M.L., Pilcher J., et al. Stability of long-term renal function in heart transplant patients treated with induction therapy and low-dose cyclosporine. J Heart Lung Transplant. 11:1992;926.
10. Cantarovich M., Fitchett D., Latter D. Cyclosporine trough levels, acute rejection, and renal dysfunction after heart transplantation. Transplantation. 59:1995;444.
11. Ojo A.O., Held P.J., Port F.K., et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 349:2003;931.
12. Holt D.W., Mueller E.A., Kovarick J.M., et al. The pharmacokinetics of Sandimmune Neoral A new oral formulation of cyclosporine. Transplant Proc. 26:1994;2935.
13. Warrens A.N., Salama A., Waters J.B., et al. Comparison of Neoral and Sandimmune preparations in renal transplant patients - improved pharmacokinetics with Neoral. Transplant Proc. 28:1996;2169.
14. Kahan B.D. Pharmacokinetic considerations in the therapeutic application of cyclosporine in renal transplantation. Transplant Proc. 28:1996;2143.
15. Keown P.A. Use of cyclosporine microemulsion (Neoral) in de novo and stable renal transplantation clinical impact, pharmacokinetic consequences and economic benefits. Transplant Proc. 28:1996;2147.
16. Kovarik J.M., Mueller E.A., Richard F., et al. Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation. Transplantation. 62:1996;759.
17. Kahan B.D., Dunn J., Fitts C., et al. The Neoral formulation improved correlation between cyclosporine trough levels and exposure in stable renal transplant recipients. Transplant Proc. 26:1994;2940.
18. Cole E., Keown P., Landsberg D., et al. Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18 months of follow-up in stable renal transplant recipients a report of the Canadian Neoral Renal Study Group. Transplantation. 65:1998;505.
19. Foradori A.C., Martinez L., Vacarezza A., et al. Pharmacokinetics of a new galenical formulation of oral cyclosporine A in stable kidney transplanted patients. Transplant Proc. 26:1994;2969.
20. Amante A.J., Kahan B.D. Abbreviated AUC strategy for monitoring cyclosporine microemulsion therapy in the immediate posttransplant period. Transplant Proc. 28:1996;2162.
21. Keown P., Landsberg D., Halloran P., et al. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group. Transplantation. 62:1996;1744.
22. Gaspari F., Anedda M.F., Signorini O., et al. Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administration. J Am Soc Nephrol. 8:1997;647.
23. Cantarovich M., Besner J.G., Barkun J.S., et al. Two hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant. 12:1998;243.
24. Roubenoff R., Drew H., Moyer M., et al. Oral cimetidine improves the accuracy and precision of creatinine clearance in lupus nephritis. Ann Intern Med. 113:1990;501.
25. Hilbrands L.B., Artz M.A., Wetzels J.F.M., et al. Cimetidine improves the reliability of creatinine as a marker of glomerular filtration. Kidney Int. 40:1991;1171.
26. Cantarovich M, Giannetti N, Cecere R, et al: Single time point predictors of cyclosporine microemulsion and of mycophenolic acid area-under-the-curve (AUC0-12 hr) in long-term heart transplant patients. Am J Transplant 3(Suppl 5):168, 2003.
27. Cantarovich M., Elstein E., de Varennes B., et al. Clinical benefit of Neoral dose monitoring with cyclosporine 2-hour post dose levels compared to trough levels in stable heart transplant patients. Transplantation. 68:1999;1839.
28. Delgado D., Cusimano R.J., Feindel C., et al. Monitoring of cyclosporine 2-hr post-dose and trough levels in heart transplantation. J Heart Lung Transplant. 21:2002;102.
29. Cantarovich M., Quantz M., Elstein E., et al. Neoral dose monitoring with cyclosporine 2-hour postdose levels in heart transplant patients receiving anti-thymocyte globulin induction. Transplant Proc. 32:2000;446.
30. Billingham M.E., Cary N.R., Hammond M.E., et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection Heart Rejection Study Group. J Heart Transplant. 6:1990;587.
31. Cantarovich M., Giannetti N., Cecere R. Impact of cyclosporine 2-hour level and of mycophenolate mofetil dose on clinical outcomes in de novo heart transplant patients receiving anti-thymocyte globulin induction. Clin Transplant. 17:2003;144.
32. Cantarovich M, Giannetti N, Cecere R: Relationship between endomyocardial biopsy score and cyclosporine 2-hour peak levels during the first year after heart transplantation. Clin Transplant (in press), 2004.
33. Levy G., Burra P., Cavallari A., et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2). Transplantation. 73:2002;953.
34. International Neoral Renal Transplantation Study Group. Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis. Am J Transplant. 2:2002;157.
35. Cooney G.F., Johnston A. Neoral C-2 monitoring in cardiac transplant patients. Transplant Proc. 33:2001;1572.
36. Cantarovich M., Barkun J.S., Tchervenkov J.I., et al. Comparison of Neoral dose monitoring with cyclosporine trough levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation. 12:1998;1621.
37. Levy G., Smith R., O'Grady C., et al. Long term follow up of maintenance liver transplant patients converted to C2 cyclosporine using Neoral immunosuppression. Am J Transplant. 3:2002;370.
38. Levy G., Lilly L.B., Grant D.R., et al. Once daily dosing with Neoral utilizing C2 monitoring in maintenance liver transplant patients. Am J Transplant. 5:2003;422.
39. Grant D., Kneteman N., Tchervenkov J., et al. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection results of a prospective, randomized comparison of Neoral and Sandimmune for liver transplantation (NOF-8). Transplantation. 67:1999;1133.
40. Baraldo M., Risaliti A., Bresadola F., et al. Circadian variations in cyclosporine C2 concentrations during the first 2 weeks after liver transplantation. Transplant Proc. 35:2003;1449.
41. Batiuk T.D., Pazderka F., Enns J., et al. Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible. J Clin Invest. 96:1995;1254.
42. Sindhi R., LaVia M.F., Paulling E., et al. Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine + rapamycin regimen. Transplantation. 69:2000;432.